文献速递淋巴瘤

低剂量中度大分割放疗治疗惰性非霍奇金淋巴瘤:一项多中心、单臂、2期试验

Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2025-05-02

这项多中心单臂2期试验纳入中国四家医院的71例惰性非霍奇金淋巴瘤患者(73个靶区),接受12 Gy分4次累及部位放疗。中位随访19个月,6个月完全缓解率为95%(95% CI 87-98;73个靶区中69个)。最常见急性不良事件为1级淋巴细胞减少(71例中20例,28%)和1级恶心(73个靶区中14个,19%),唯一≥3级不良事件为3级淋巴细胞减少(71例中8例,11%),无治疗相关死亡。

要点

  • 12 Gy分4次放疗的6个月完全缓解率为95%(95% CI 87-98;73个靶区中69个)。
  • 最常见急性不良事件为1级淋巴细胞减少(28%)和1级恶心(19%)。
  • 唯一≥3级不良事件为3级淋巴细胞减少(11%),无治疗相关死亡。

核心结论

  • 12 Gy分4次方案作为惰性非霍奇金淋巴瘤的局部治疗是安全的,并显示出有前景的活性。
  • 鉴于该试验为回顾性注册,需要进一步研究评估该策略的疗效。

研究设计与样本

  • 多中心、单臂、2期试验,纳入中国四家医院的患者。
  • 入组标准为年龄18岁及以上、新诊断或复发的I-IV期惰性非霍奇金淋巴瘤(滤泡性淋巴瘤、边缘区淋巴瘤和低级别淋巴瘤)、ECOG体能状态0-3分。
  • 患者接受累及部位放疗,剂量为12 Gy分4次。
  • 主要终点为放疗后6个月的完全缓解率,所有分析在意向治疗人群中进行。
  • 试验注册于ClinicalTrials.gov(NCT05543070),因COVID-19大流行延迟四个月注册;招募已完成,随访正在进行中。

主要发现

  • 2022年5月8日至2023年11月8日共入组71例患者(73个靶区),中位年龄55岁(IQR 48-65);29例(41%)男性,42例(59%)女性;均为亚洲人。
  • 中位随访19个月(IQR 16-22),6个月完全缓解率为95%(95% CI 87-98;73个靶区中69个)。
  • 最常见急性不良事件为1级淋巴细胞减少(71例中20例,28%)和1级恶心(73个靶区中14个,19%)。
  • 唯一≥3级不良事件为3级淋巴细胞减少(71例中8例,11%),无治疗相关死亡。

局限性

  • 原文指出该试验为回顾性注册。
  • 原文结论提出需要进一步研究评估该策略的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy for indolent non-Hodgkin lymphoma has evolved to optimise the definitive dose while minimising toxicity. We aimed to assess the activity and safety of a hypofractionated low-dose radiotherapy regimen of 12 Gy in four fractions in patients with indolent non-Hodgkin lymphoma. METHODS: This multicentre, single-arm, phase 2 trial study enrolled patients from four hospitals in China. Patients aged 18 years or older with newly diagnosed or relapsed stage I-IV indolent non-Hodgkin lymphoma (follicular lymphoma, marginal zone lymphoma, and low-grade lymphoma) and an Eastern Cooperative Oncology Group performance status of 0-3 were eligible. Patients underwent involved-site radiotherapy at a dose of 12 Gy in four fractions. The primary endpoint was the complete response rate 6 months after radiotherapy. All analyses were performed in the intention-to-treat population. This trial was registered with ClinicalTrials.gov, NCT05543070, with a four-month delay due to the COVID-19 pandemic; recruitment is complete and follow-up is ongoing. FINDINGS: Between May 8, 2022, and Nov 8, 2023, 71 patients (with 73 target sites) were enrolled (median age 55 years [IQR 48-65]; 29 [41%] male and 42 [59%] female; and all were Asian). With a median follow-up of 19 months (IQR 16-22), the 6-month complete response was 95% (95% CI 87-98; 69 of 73 sites). The most common acute adverse events were grade 1 lymphopenia (20 [28%] of 71 patients) and grade 1 nausea (14 [19%] of 73 sites). The sole grade 3 or higher adverse event was grade 3 lymphopenia (eight [11%] of 71 patients). No treatment-related deaths were noted. INTERPRETATION: The regimen of 12 Gy in four fractions is safe and shows promising activity as a local treatment for patients with indolent non-Hodgkin lymphoma. Given the retrospective registration of the trial, further studies evaluating the efficacy of this strategy are warranted. FUNDING: The Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences, the National High Level Hospital Clinical Research Funding, and the Beijing Hope Run Special Fund of Cancer Foundation of China.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Wang XY, Zhang XM, Wang L, et al. Low-dose moderate hypofractionated radiotherapy for indolent non-Hodgkin lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025. PMID: 40324445. doi:10.1016/S2352-3026(25)00071-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。